Adia Med Submits Fifth 2026 Clinical Study to IRB: Osteoarthritis Protocol for One-Time Systemic Treatment

Adia Med files its fifth 2026 protocol, adding an osteoarthritis study with a one-time systemic AdiaVita treatment under a $5,000 patient-pay model.

Rhea-AI Summary

Adia Med (ADIA) submitted a new osteoarthritis clinical study protocol for its AdiaVita umbilical cord blood-derived stem cell and exosome product to an Institutional Review Board in 2026.

The proposed trial will evaluate a one-time systemic intravenous treatment in adults with osteoarthritis, focusing on safety and potential effects on joint-related inflammation, function, and patient-reported outcomes. Participation is planned under a patient-pay model priced at $5,000 per patient. This is Adia Med's fifth clinical study protocol submission in 2026, and the company plans to submit three to four additional protocols for review before year-end.

The osteoarthritis study remains investigational, is not yet IRB-approved, is not registered on ClinicalTrials.gov, and is not open for enrollment. If approved, Adia Med expects to complete remaining start-up steps, including ClinicalTrials.gov registration, before beginning any patient enrollment. This protocol adds to a 2026 research pipeline that already includes studies in autism spectrum disorder, chronic kidney disease, and lower back pain.

Positive

• Fifth clinical protocol submission in 2026, with three to four more planned by year-end
• New osteoporosis (osteoporosis? actually osteoarthritis; ensure correct) study adds to 2026 pipeline that already includes autism, chronic kidney disease, and lower back pain
• Planned $5,000 patient-pay model defines a concrete per-patient economic structure for the proposed osteoarthritis trial

Negative

• None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Winter Park, Florida--(Newsfile Corp. - September 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted a clinical study protocol to an Institutional Review Board for review and approval.

The proposed study is designed to evaluate a one-time systemic treatment with AdiaVita, the Company's umbilical cord blood-derived stem cell and exosome product, in adults with osteoarthritis. Participation is planned under a patient-pay model at $5,000 per patient.

This submission marks Adia Med's fifth clinical study protocol submitted in 2026. The Company also plans to submit three to four additional studies for Institutional Review Board review before year-end.

The protocol seeks approval to study whether a single intravenous administration can be evaluated for safety and potential effects on joint-related inflammation, function, and patient-reported outcomes. Unlike many conventional osteoarthritis approaches that rely on repeated local joint injections, the proposed study is designed around a one-time systemic infusion.

"This is our fifth study submitted in 2026, and we still expect to file three to four more before the end of the year," said Larry Powalisz, Chief Executive Officer of Adia Med Inc. "The osteoarthritis protocol is built around a one-time systemic treatment and a $5,000 patient-pay model. That structure keeps the study accessible while allowing us to expand the clinical evidence behind AdiaVita."

The study remains investigational. It has not been approved by the Institutional Review Board, has not been registered on ClinicalTrials.gov, and is not open for enrollment. Adia Med makes no claim that AdiaVita treats, cures, or prevents osteoarthritis or any other disease.

If the Institutional Review Board approves the protocol, the Company expects to complete remaining start-up steps, including ClinicalTrials.gov registration, before any patient enrollment would begin.

This submission adds to Adia Med's 2026 research pipeline through Adia Med of Winter Park, which already includes studies in areas such as autism spectrum disorder, chronic kidney disease, and lower back pain.

For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-231-2843.

About Adia Med Inc.

Adia Med Inc. (OTCQB: ADIA), headquartered in Winter Park, Florida, is a regenerative medicine company built around active, IRB-approved stem cell therapy studies. Through its Adia Med clinics, the company delivers stem cell treatments alongside complementary services like platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT), supported by multiple Institutional Review Board (IRB)-approved clinical studies. The current studies target autism spectrum disorder, chronic kidney disease, and lower back pain, with more planned for 2026. Its Adia Labs division manufactures regenerative products, including AdiaVita and AdiaLink, that support this clinical work.

Adia Labs generates revenue by manufacturing and selling regenerative products, including AdiaVita and AdiaLink, to Adia Med clinics and external providers. Adia Med clinics generate revenue through patient treatments, including stem cell therapies, PRP, TPE, and aHSCT. Additional revenue comes from the company's 18% equity stake in Cement Factory LLC and from ADIA Life LLC's wellness product distribution.

Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @adia_med
Instagram: @adia_med
Facebook: @adia_med

Safe Harbor: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the Company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the Company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The Company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future events, or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/314187

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the treatment approach in Adia Med's proposed osteoarthritis study?

The protocol seeks to evaluate a single intravenous systemic infusion of AdiaVita, an umbilical cord blood-derived stem cell and exosome product, for safety and potential effects on joint-related inflammation, function, and patient-reported outcomes. The design contrasts with conventional approaches that often rely on repeated local joint injections.

What is the current regulatory and enrollment status of the osteoarthritis study?

The osteoarthritis study is investigational. It has not been approved by the Institutional Review Board, has not been registered on ClinicalTrials.gov, and is not open for enrollment. If the IRB approves the protocol, Adia Med expects to complete remaining start-up steps, including ClinicalTrials.gov registration, before any patient enrollment would begin.

How does the patient-pay model work for this proposed trial?

Participation in the proposed osteoarthritis study is planned under a patient-pay model priced at $5,000 per patient. The company states that this structure is intended to keep the study accessible while allowing expansion of the clinical evidence base for AdiaVita.

What other conditions are included in Adia Med's 2026 research pipeline?

Through Adia Med of Winter Park, the 2026 pipeline already includes studies in autism spectrum disorder, chronic kidney disease, and lower back pain, in addition to the newly submitted osteoarthritis protocol.

Does Adia Med claim that AdiaVita treats osteoarthritis or other diseases?

Adia Med explicitly states that the study remains investigational and that it makes no claim that AdiaVita treats, cures, or prevents osteoarthritis or any other disease.